Oramed Pharmaceuticals (ORMP) Net Equity Issued and Repurchased (2010 - 2023)

Oramed Pharmaceuticals' Net Equity Issued and Repurchased history runs 13 years deep, the most recent figure standing at -$2000.0 for Q3 2023.

• Quarterly Net Equity Issued and Repurchased fell 100.05% year-over-year to -$2000.0 in Q3 2023, while the trailing twelve-month figure through Dec 2023 was $2.4 million (down 78.89% YoY) and the FY2023 annual result came in at $2.4 million, down 78.89% from the prior year.
• Net Equity Issued and Repurchased was -$2000.0 for Q3 2023 at Oramed Pharmaceuticals, down from $2.4 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $20.0 million in Q2 2020 and bottomed at -$7.6 million in Q2 2022.
• A 5-year average of $4.7 million and a median of $3.3 million in 2022 frame the typical range for Net Equity Issued and Repurchased.
• Peak annual rise in Net Equity Issued and Repurchased reached 77.11% in 2023, while the deepest fall reached 100.05% in 2023.
• Oramed Pharmaceuticals' Net Equity Issued and Repurchased stood at $1000.0 in 2019, then soared by 1997800.0% to $20.0 million in 2020, then sank by 46.86% to $10.6 million in 2021, then plunged by 60.86% to $4.2 million in 2022, then tumbled by 100.05% to -$2000.0 in 2023.
• Business Quant data shows ORMP's Net Equity Issued and Repurchased at -$2000.0 in Q3 2023, $2.4 million in Q1 2023, and $4.2 million in Q4 2022.